Sequencing.com, a biotech company offering the world’s largest platform for whole genome sequencing and personalized health insights, announced a strategic partnership with PGxAI, a leader in AI-driven pharmacogenomics. This collaboration will transform the pharmacogenomics field by combining cutting-edge genomic insights with real-world healthcare applications, ultimately enhancing patient outcomes and reducing adverse drug reactions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819016399/en/

Sequencing.com Announces Strategic Partnership with PGxAI to Drive Affordable Healthcare Through Advanced Pharmacogenomics

As part of this initiative, PGxAI will roll out a suite of pharmacogenomic reports on Sequencing.com that provide personalized drug implications based on an individual’s genomic data. They directly address a critical healthcare need — reducing adverse drug reaction incidences, a leading cause of unnecessary healthcare costs and patient harm. The reports cover over 730 drugs and 40 genes — offering up to five times the coverage of competitors.

“Adverse drug reactions account for over $150 billion in excess healthcare costs annually in the U.S.,” said Allan Gobbs, PGxAI Executive Chairman and Co-Founder. “Studies indicate that pharmacogenomics can reduce these incidents by 30%, representing a significant opportunity to optimize healthcare costs and make treatments more affordable and effective.”

Dr. Brandon Colby, Sequencing.com Founder and CEO, added, “The demand for pharmacogenomic testing is rapidly growing. PGxAI’s scientific rigor and comprehensive data coverage provide unmatched value to our customers, further driving the precision health movement.”

“More than 99% of individuals carry clinically relevant drug-gene variations,” said Dr. Mike Zack, PGxAI CEO and Co-Founder. “Leveraging this information enables safer, more effective treatment regimens, making precision pharmacogenomics an immediate reality for modern healthcare.”

PGxAI’s reports seamlessly integrate with major reporting formats from clinically actionable consumer genetic testing services. These integrations allow users to effortlessly upload their genetic data, unlocking actionable insights linked to FDA guidelines and leading pharmacogenomics consortiums. These reports also represent new revenue opportunities for laboratories working with genomic data. Zack emphasized, “Our reports are plug-and-play for genomic labs, offering new revenue streams while delivering measurable benefits for patients.”

Learn more about this partnership at www.sequencing.com/marketplace/medications-pgx-complete-dna-guide.

About Sequencing.com

Founded in 2017 by Dr. Brandon Colby and based in Los Angeles, Sequencing.com (Sequencing) is a biotech company offering the world’s largest platform for whole genome sequencing and personalized health insights. While most DNA tests obtain less than 0.1% of DNA data, Sequencing DNA test bundles allow users to obtain 100% of their DNA sequencing data, and the company offers the most private DNA sequencing test on the market. Led by US medical doctors, geneticists, bioinformatics experts, and software developers, Sequencing helps users make proactive decisions with their healthcare provider and genetic counselors around rare diseases, cancer risks, autoimmune disorders, cardiovascular health, and much more. Learn more at Sequencing.com, LinkedIn, Instagram, TikTok, X, and Facebook.

About PGxAI

Launched in 2023, Palo Alto‑based PGxAI stands at the forefront of pharmacogenomics, leveraging AI and real-world data to drive innovation in precision medicine. The platform employs proprietary algorithms to personalize drug selection, dosage, and interaction management. PGxAI is led by a team of scientists, AI experts and serial entrepreneurs, including CEO and сo-founder Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, and executive chairman and сo-founder Allan Gobbs, a seasoned Life Sciences VC. The advisory board includes Dr. Russ Altman of Stanford University and executives from Thermo Fisher, GE Healthcare, and Tempus AI. Backed by New York-based ATEM Capital and in strategic partnership with InterSystems, PGxAI seeks to address the critical need for tailored, effective therapies in healthcare, and set new standards for precision medicine.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250819016399/en/

Sequencing.com Announces Strategic Partnership with PGxAI to Drive Affordable Healthcare Through Advanced Pharmacogenomics